Close

EGFRvA

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Epidermal growth factor receptor (EGFR) is a transmembrane protein that is activated by binding of its specific ligands. Epidermal growth factor receptor isoform (EGFRvA) has higher tumor-promoting capacity than EGFR. Moreover, EGFRvA is more stable than EGFR because of its decreased binding to E3 ubiquitin ligase c-CbI. EGFRvA as a drug target is associated with lung cancer, colon cancer, anal cancer, glioblastoma and epithelian tumors of the head and neck.

Associated Disease
  • Lung cancer
  • Colon cancer
  • Anal cancer
  • Glioblastoma
  • Epithelian tumors of the head and neck
  • Others
  • CAR Vector Products

  • CAR Viral Particles

Loading...
  • Target Species:
  • Antibody Clone:
  • Antibody Host:
  • Receptor Construction:
  • Vector Type:
  • Targeting Cell Type:
CAT Product Name Target Species Antibody Clone Antibody Host Receptor Construction Vector Type Targeting Cell Type CAR Vector Type Inquiry & Datasheet
CAR-MZ187 Anti-EGFRvA (2D3) h(CD3ζ) CAR, pCDCAR1 Human 2D3 Mouse scFv-CD3ζ Lentiviral T cell   Add to Cart   Datasheet
CAR-MZ188 Anti-EGFRvA (2D3) h(CD28-CD3ζ) CAR, pCDCAR1 Human 2D3 Mouse scFv-CD28-CD3ζ Lentiviral T cell   Add to Cart   Datasheet
CAR-MZ189 Anti-EGFRvA (2D3) h(41BB-CD3ζ) CAR, pCDCAR1 Human 2D3 Mouse scFv-41BB-CD3ζ Lentiviral T cell   Add to Cart   Datasheet
CAR-MZ190 Anti-EGFRvA (2D3) h(CD28-41BB-CD3ζ) CAR, pCDCAR1 Human 2D3 Mouse scFv-CD28-41BB-CD3ζ Lentiviral T cell   Add to Cart   Datasheet
Unable to find the desired product? Explore the Filter Options at the top of the list.
Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.